Molecular-Targeted Drugs in Rheumatology

Cell-surface antigens, cytokines, receptors, and signal transduction molecules that are central in the pathogenesis of rheumatic diseases have been elucidated, and therapeutic targets have been identified. Molecular-targeted drugs are now available for the treatment of rheumatoid arthritis and other...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Eiichi Tanaka [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2023

Schlagwörter:	biological disease-modifying anti-rheumatic drugs janus kinase inhibitors molecular-targeted drugs rheumatoid arthritis rheumatic diseases

Übergeordnetes Werk:	In: Tokyo Women's Medical University Journal - Society of Tokyo Women's Medical University, 2021, 7(2023), 0, Seite 21-33
Übergeordnetes Werk:	volume:7 ; year:2023 ; number:0 ; pages:21-33

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.24488/twmuj.2023013

Katalog-ID:	DOAJ098147579

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ098147579
003	DE-627
005	20240413205201.0
007	cr uuu---uuuuu
008	240413s2023 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.24488/twmuj.2023013 \|2 doi
035			\|a (DE-627)DOAJ098147579
035			\|a (DE-599)DOAJ5084a4e248ad4c1baba7559183723690
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	0		\|a Eiichi Tanaka \|e verfasserin \|4 aut
245	1	0	\|a Molecular-Targeted Drugs in Rheumatology
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Cell-surface antigens, cytokines, receptors, and signal transduction molecules that are central in the pathogenesis of rheumatic diseases have been elucidated, and therapeutic targets have been identified. Molecular-targeted drugs are now available for the treatment of rheumatoid arthritis and other diseases, including psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. These targeted drugs have shown the potential for achieving clinical remission in many rheumatic diseases. Tumor necrosis factor and interleukin-6 (IL-6) play major roles in rheumatoid arthritis, whereas IL-17 and IL-23 play crucial roles in spondyloarthritis. Biological disease-modifying anti-rheumatic drugs that specifically inhibit the actions of these cytokines and targeted synthetic disease-modifying anti-rheumatic drugs, such as Janus kinase inhibitors, have been approved, increasing the available treatment options. Molecular-targeted drugs also hold promise for the treatment of collagen diseases, including systemic lupus erythematosus, systemic sclerosis, and vasculitis. However, drawbacks related to their use persist, including high drug costs and the risk of adverse events, such as infectious diseases. Therefore, the criteria for selecting patients who are most likely to benefit from these drugs should be developed.
650		4	\|a biological disease-modifying anti-rheumatic drugs
650		4	\|a janus kinase inhibitors
650		4	\|a molecular-targeted drugs
650		4	\|a rheumatoid arthritis
650		4	\|a rheumatic diseases
653		0	\|a Medicine
653		0	\|a R
773	0	8	\|i In \|t Tokyo Women's Medical University Journal \|d Society of Tokyo Women's Medical University, 2021 \|g 7(2023), 0, Seite 21-33 \|w (DE-627)1751181464 \|x 24326186 \|7 nnns
773	1	8	\|g volume:7 \|g year:2023 \|g number:0 \|g pages:21-33
856	4	0	\|u https://doi.org/10.24488/twmuj.2023013 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/5084a4e248ad4c1baba7559183723690 \|z kostenfrei
856	4	0	\|u https://www.jstage.jst.go.jp/article/twmuj/7/0/7_2023013/_pdf/-char/en \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2432-6186 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 7 \|j 2023 \|e 0 \|h 21-33

Indexfelder

author_variant	e t et
matchkey_str	article:24326186:2023----::oeuatreedusnh
hierarchy_sort_str	2023
publishDate	2023
allfields	10.24488/twmuj.2023013 doi (DE-627)DOAJ098147579 (DE-599)DOAJ5084a4e248ad4c1baba7559183723690 DE-627 ger DE-627 rakwb eng Eiichi Tanaka verfasserin aut Molecular-Targeted Drugs in Rheumatology 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cell-surface antigens, cytokines, receptors, and signal transduction molecules that are central in the pathogenesis of rheumatic diseases have been elucidated, and therapeutic targets have been identified. Molecular-targeted drugs are now available for the treatment of rheumatoid arthritis and other diseases, including psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. These targeted drugs have shown the potential for achieving clinical remission in many rheumatic diseases. Tumor necrosis factor and interleukin-6 (IL-6) play major roles in rheumatoid arthritis, whereas IL-17 and IL-23 play crucial roles in spondyloarthritis. Biological disease-modifying anti-rheumatic drugs that specifically inhibit the actions of these cytokines and targeted synthetic disease-modifying anti-rheumatic drugs, such as Janus kinase inhibitors, have been approved, increasing the available treatment options. Molecular-targeted drugs also hold promise for the treatment of collagen diseases, including systemic lupus erythematosus, systemic sclerosis, and vasculitis. However, drawbacks related to their use persist, including high drug costs and the risk of adverse events, such as infectious diseases. Therefore, the criteria for selecting patients who are most likely to benefit from these drugs should be developed. biological disease-modifying anti-rheumatic drugs janus kinase inhibitors molecular-targeted drugs rheumatoid arthritis rheumatic diseases Medicine R In Tokyo Women's Medical University Journal Society of Tokyo Women's Medical University, 2021 7(2023), 0, Seite 21-33 (DE-627)1751181464 24326186 nnns volume:7 year:2023 number:0 pages:21-33 https://doi.org/10.24488/twmuj.2023013 kostenfrei https://doaj.org/article/5084a4e248ad4c1baba7559183723690 kostenfrei https://www.jstage.jst.go.jp/article/twmuj/7/0/7_2023013/_pdf/-char/en kostenfrei https://doaj.org/toc/2432-6186 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2023 0 21-33
spelling	10.24488/twmuj.2023013 doi (DE-627)DOAJ098147579 (DE-599)DOAJ5084a4e248ad4c1baba7559183723690 DE-627 ger DE-627 rakwb eng Eiichi Tanaka verfasserin aut Molecular-Targeted Drugs in Rheumatology 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cell-surface antigens, cytokines, receptors, and signal transduction molecules that are central in the pathogenesis of rheumatic diseases have been elucidated, and therapeutic targets have been identified. Molecular-targeted drugs are now available for the treatment of rheumatoid arthritis and other diseases, including psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. These targeted drugs have shown the potential for achieving clinical remission in many rheumatic diseases. Tumor necrosis factor and interleukin-6 (IL-6) play major roles in rheumatoid arthritis, whereas IL-17 and IL-23 play crucial roles in spondyloarthritis. Biological disease-modifying anti-rheumatic drugs that specifically inhibit the actions of these cytokines and targeted synthetic disease-modifying anti-rheumatic drugs, such as Janus kinase inhibitors, have been approved, increasing the available treatment options. Molecular-targeted drugs also hold promise for the treatment of collagen diseases, including systemic lupus erythematosus, systemic sclerosis, and vasculitis. However, drawbacks related to their use persist, including high drug costs and the risk of adverse events, such as infectious diseases. Therefore, the criteria for selecting patients who are most likely to benefit from these drugs should be developed. biological disease-modifying anti-rheumatic drugs janus kinase inhibitors molecular-targeted drugs rheumatoid arthritis rheumatic diseases Medicine R In Tokyo Women's Medical University Journal Society of Tokyo Women's Medical University, 2021 7(2023), 0, Seite 21-33 (DE-627)1751181464 24326186 nnns volume:7 year:2023 number:0 pages:21-33 https://doi.org/10.24488/twmuj.2023013 kostenfrei https://doaj.org/article/5084a4e248ad4c1baba7559183723690 kostenfrei https://www.jstage.jst.go.jp/article/twmuj/7/0/7_2023013/_pdf/-char/en kostenfrei https://doaj.org/toc/2432-6186 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2023 0 21-33
allfields_unstemmed	10.24488/twmuj.2023013 doi (DE-627)DOAJ098147579 (DE-599)DOAJ5084a4e248ad4c1baba7559183723690 DE-627 ger DE-627 rakwb eng Eiichi Tanaka verfasserin aut Molecular-Targeted Drugs in Rheumatology 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cell-surface antigens, cytokines, receptors, and signal transduction molecules that are central in the pathogenesis of rheumatic diseases have been elucidated, and therapeutic targets have been identified. Molecular-targeted drugs are now available for the treatment of rheumatoid arthritis and other diseases, including psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. These targeted drugs have shown the potential for achieving clinical remission in many rheumatic diseases. Tumor necrosis factor and interleukin-6 (IL-6) play major roles in rheumatoid arthritis, whereas IL-17 and IL-23 play crucial roles in spondyloarthritis. Biological disease-modifying anti-rheumatic drugs that specifically inhibit the actions of these cytokines and targeted synthetic disease-modifying anti-rheumatic drugs, such as Janus kinase inhibitors, have been approved, increasing the available treatment options. Molecular-targeted drugs also hold promise for the treatment of collagen diseases, including systemic lupus erythematosus, systemic sclerosis, and vasculitis. However, drawbacks related to their use persist, including high drug costs and the risk of adverse events, such as infectious diseases. Therefore, the criteria for selecting patients who are most likely to benefit from these drugs should be developed. biological disease-modifying anti-rheumatic drugs janus kinase inhibitors molecular-targeted drugs rheumatoid arthritis rheumatic diseases Medicine R In Tokyo Women's Medical University Journal Society of Tokyo Women's Medical University, 2021 7(2023), 0, Seite 21-33 (DE-627)1751181464 24326186 nnns volume:7 year:2023 number:0 pages:21-33 https://doi.org/10.24488/twmuj.2023013 kostenfrei https://doaj.org/article/5084a4e248ad4c1baba7559183723690 kostenfrei https://www.jstage.jst.go.jp/article/twmuj/7/0/7_2023013/_pdf/-char/en kostenfrei https://doaj.org/toc/2432-6186 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2023 0 21-33
allfieldsGer	10.24488/twmuj.2023013 doi (DE-627)DOAJ098147579 (DE-599)DOAJ5084a4e248ad4c1baba7559183723690 DE-627 ger DE-627 rakwb eng Eiichi Tanaka verfasserin aut Molecular-Targeted Drugs in Rheumatology 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cell-surface antigens, cytokines, receptors, and signal transduction molecules that are central in the pathogenesis of rheumatic diseases have been elucidated, and therapeutic targets have been identified. Molecular-targeted drugs are now available for the treatment of rheumatoid arthritis and other diseases, including psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. These targeted drugs have shown the potential for achieving clinical remission in many rheumatic diseases. Tumor necrosis factor and interleukin-6 (IL-6) play major roles in rheumatoid arthritis, whereas IL-17 and IL-23 play crucial roles in spondyloarthritis. Biological disease-modifying anti-rheumatic drugs that specifically inhibit the actions of these cytokines and targeted synthetic disease-modifying anti-rheumatic drugs, such as Janus kinase inhibitors, have been approved, increasing the available treatment options. Molecular-targeted drugs also hold promise for the treatment of collagen diseases, including systemic lupus erythematosus, systemic sclerosis, and vasculitis. However, drawbacks related to their use persist, including high drug costs and the risk of adverse events, such as infectious diseases. Therefore, the criteria for selecting patients who are most likely to benefit from these drugs should be developed. biological disease-modifying anti-rheumatic drugs janus kinase inhibitors molecular-targeted drugs rheumatoid arthritis rheumatic diseases Medicine R In Tokyo Women's Medical University Journal Society of Tokyo Women's Medical University, 2021 7(2023), 0, Seite 21-33 (DE-627)1751181464 24326186 nnns volume:7 year:2023 number:0 pages:21-33 https://doi.org/10.24488/twmuj.2023013 kostenfrei https://doaj.org/article/5084a4e248ad4c1baba7559183723690 kostenfrei https://www.jstage.jst.go.jp/article/twmuj/7/0/7_2023013/_pdf/-char/en kostenfrei https://doaj.org/toc/2432-6186 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2023 0 21-33
allfieldsSound	10.24488/twmuj.2023013 doi (DE-627)DOAJ098147579 (DE-599)DOAJ5084a4e248ad4c1baba7559183723690 DE-627 ger DE-627 rakwb eng Eiichi Tanaka verfasserin aut Molecular-Targeted Drugs in Rheumatology 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cell-surface antigens, cytokines, receptors, and signal transduction molecules that are central in the pathogenesis of rheumatic diseases have been elucidated, and therapeutic targets have been identified. Molecular-targeted drugs are now available for the treatment of rheumatoid arthritis and other diseases, including psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. These targeted drugs have shown the potential for achieving clinical remission in many rheumatic diseases. Tumor necrosis factor and interleukin-6 (IL-6) play major roles in rheumatoid arthritis, whereas IL-17 and IL-23 play crucial roles in spondyloarthritis. Biological disease-modifying anti-rheumatic drugs that specifically inhibit the actions of these cytokines and targeted synthetic disease-modifying anti-rheumatic drugs, such as Janus kinase inhibitors, have been approved, increasing the available treatment options. Molecular-targeted drugs also hold promise for the treatment of collagen diseases, including systemic lupus erythematosus, systemic sclerosis, and vasculitis. However, drawbacks related to their use persist, including high drug costs and the risk of adverse events, such as infectious diseases. Therefore, the criteria for selecting patients who are most likely to benefit from these drugs should be developed. biological disease-modifying anti-rheumatic drugs janus kinase inhibitors molecular-targeted drugs rheumatoid arthritis rheumatic diseases Medicine R In Tokyo Women's Medical University Journal Society of Tokyo Women's Medical University, 2021 7(2023), 0, Seite 21-33 (DE-627)1751181464 24326186 nnns volume:7 year:2023 number:0 pages:21-33 https://doi.org/10.24488/twmuj.2023013 kostenfrei https://doaj.org/article/5084a4e248ad4c1baba7559183723690 kostenfrei https://www.jstage.jst.go.jp/article/twmuj/7/0/7_2023013/_pdf/-char/en kostenfrei https://doaj.org/toc/2432-6186 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2023 0 21-33
language	English
source	In Tokyo Women's Medical University Journal 7(2023), 0, Seite 21-33 volume:7 year:2023 number:0 pages:21-33
sourceStr	In Tokyo Women's Medical University Journal 7(2023), 0, Seite 21-33 volume:7 year:2023 number:0 pages:21-33
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	biological disease-modifying anti-rheumatic drugs janus kinase inhibitors molecular-targeted drugs rheumatoid arthritis rheumatic diseases Medicine R
isfreeaccess_bool	true
container_title	Tokyo Women's Medical University Journal
authorswithroles_txt_mv	Eiichi Tanaka @@aut@@
publishDateDaySort_date	2023-01-01T00:00:00Z
hierarchy_top_id	1751181464
id	DOAJ098147579
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ098147579</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413205201.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.24488/twmuj.2023013</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ098147579</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ5084a4e248ad4c1baba7559183723690</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Eiichi Tanaka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Molecular-Targeted Drugs in Rheumatology</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cell-surface antigens, cytokines, receptors, and signal transduction molecules that are central in the pathogenesis of rheumatic diseases have been elucidated, and therapeutic targets have been identified. Molecular-targeted drugs are now available for the treatment of rheumatoid arthritis and other diseases, including psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. These targeted drugs have shown the potential for achieving clinical remission in many rheumatic diseases. Tumor necrosis factor and interleukin-6 (IL-6) play major roles in rheumatoid arthritis, whereas IL-17 and IL-23 play crucial roles in spondyloarthritis. Biological disease-modifying anti-rheumatic drugs that specifically inhibit the actions of these cytokines and targeted synthetic disease-modifying anti-rheumatic drugs, such as Janus kinase inhibitors, have been approved, increasing the available treatment options. Molecular-targeted drugs also hold promise for the treatment of collagen diseases, including systemic lupus erythematosus, systemic sclerosis, and vasculitis. However, drawbacks related to their use persist, including high drug costs and the risk of adverse events, such as infectious diseases. Therefore, the criteria for selecting patients who are most likely to benefit from these drugs should be developed.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">biological disease-modifying anti-rheumatic drugs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">janus kinase inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">molecular-targeted drugs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">rheumatoid arthritis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">rheumatic diseases</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Tokyo Women's Medical University Journal</subfield><subfield code="d">Society of Tokyo Women's Medical University, 2021</subfield><subfield code="g">7(2023), 0, Seite 21-33</subfield><subfield code="w">(DE-627)1751181464</subfield><subfield code="x">24326186</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:0</subfield><subfield code="g">pages:21-33</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.24488/twmuj.2023013</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/5084a4e248ad4c1baba7559183723690</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.jstage.jst.go.jp/article/twmuj/7/0/7_2023013/_pdf/-char/en</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2432-6186</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2023</subfield><subfield code="e">0</subfield><subfield code="h">21-33</subfield></datafield></record></collection>
author	Eiichi Tanaka
spellingShingle	Eiichi Tanaka misc biological disease-modifying anti-rheumatic drugs misc janus kinase inhibitors misc molecular-targeted drugs misc rheumatoid arthritis misc rheumatic diseases misc Medicine misc R Molecular-Targeted Drugs in Rheumatology
authorStr	Eiichi Tanaka
ppnlink_with_tag_str_mv	@@773@@(DE-627)1751181464
format	electronic Article
delete_txt_mv	keep
author_role	aut
collection	DOAJ
remote_str	true
illustrated	Not Illustrated
issn	24326186
topic_title	Molecular-Targeted Drugs in Rheumatology biological disease-modifying anti-rheumatic drugs janus kinase inhibitors molecular-targeted drugs rheumatoid arthritis rheumatic diseases
topic	misc biological disease-modifying anti-rheumatic drugs misc janus kinase inhibitors misc molecular-targeted drugs misc rheumatoid arthritis misc rheumatic diseases misc Medicine misc R
topic_unstemmed	misc biological disease-modifying anti-rheumatic drugs misc janus kinase inhibitors misc molecular-targeted drugs misc rheumatoid arthritis misc rheumatic diseases misc Medicine misc R
topic_browse	misc biological disease-modifying anti-rheumatic drugs misc janus kinase inhibitors misc molecular-targeted drugs misc rheumatoid arthritis misc rheumatic diseases misc Medicine misc R
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Tokyo Women's Medical University Journal
hierarchy_parent_id	1751181464
hierarchy_top_title	Tokyo Women's Medical University Journal
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1751181464
title	Molecular-Targeted Drugs in Rheumatology
ctrlnum	(DE-627)DOAJ098147579 (DE-599)DOAJ5084a4e248ad4c1baba7559183723690
title_full	Molecular-Targeted Drugs in Rheumatology
author_sort	Eiichi Tanaka
journal	Tokyo Women's Medical University Journal
journalStr	Tokyo Women's Medical University Journal
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2023
contenttype_str_mv	txt
container_start_page	21
author_browse	Eiichi Tanaka
container_volume	7
format_se	Elektronische Aufsätze
author-letter	Eiichi Tanaka
doi_str_mv	10.24488/twmuj.2023013
title_sort	molecular-targeted drugs in rheumatology
title_auth	Molecular-Targeted Drugs in Rheumatology
abstract	Cell-surface antigens, cytokines, receptors, and signal transduction molecules that are central in the pathogenesis of rheumatic diseases have been elucidated, and therapeutic targets have been identified. Molecular-targeted drugs are now available for the treatment of rheumatoid arthritis and other diseases, including psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. These targeted drugs have shown the potential for achieving clinical remission in many rheumatic diseases. Tumor necrosis factor and interleukin-6 (IL-6) play major roles in rheumatoid arthritis, whereas IL-17 and IL-23 play crucial roles in spondyloarthritis. Biological disease-modifying anti-rheumatic drugs that specifically inhibit the actions of these cytokines and targeted synthetic disease-modifying anti-rheumatic drugs, such as Janus kinase inhibitors, have been approved, increasing the available treatment options. Molecular-targeted drugs also hold promise for the treatment of collagen diseases, including systemic lupus erythematosus, systemic sclerosis, and vasculitis. However, drawbacks related to their use persist, including high drug costs and the risk of adverse events, such as infectious diseases. Therefore, the criteria for selecting patients who are most likely to benefit from these drugs should be developed.
abstractGer	Cell-surface antigens, cytokines, receptors, and signal transduction molecules that are central in the pathogenesis of rheumatic diseases have been elucidated, and therapeutic targets have been identified. Molecular-targeted drugs are now available for the treatment of rheumatoid arthritis and other diseases, including psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. These targeted drugs have shown the potential for achieving clinical remission in many rheumatic diseases. Tumor necrosis factor and interleukin-6 (IL-6) play major roles in rheumatoid arthritis, whereas IL-17 and IL-23 play crucial roles in spondyloarthritis. Biological disease-modifying anti-rheumatic drugs that specifically inhibit the actions of these cytokines and targeted synthetic disease-modifying anti-rheumatic drugs, such as Janus kinase inhibitors, have been approved, increasing the available treatment options. Molecular-targeted drugs also hold promise for the treatment of collagen diseases, including systemic lupus erythematosus, systemic sclerosis, and vasculitis. However, drawbacks related to their use persist, including high drug costs and the risk of adverse events, such as infectious diseases. Therefore, the criteria for selecting patients who are most likely to benefit from these drugs should be developed.
abstract_unstemmed	Cell-surface antigens, cytokines, receptors, and signal transduction molecules that are central in the pathogenesis of rheumatic diseases have been elucidated, and therapeutic targets have been identified. Molecular-targeted drugs are now available for the treatment of rheumatoid arthritis and other diseases, including psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. These targeted drugs have shown the potential for achieving clinical remission in many rheumatic diseases. Tumor necrosis factor and interleukin-6 (IL-6) play major roles in rheumatoid arthritis, whereas IL-17 and IL-23 play crucial roles in spondyloarthritis. Biological disease-modifying anti-rheumatic drugs that specifically inhibit the actions of these cytokines and targeted synthetic disease-modifying anti-rheumatic drugs, such as Janus kinase inhibitors, have been approved, increasing the available treatment options. Molecular-targeted drugs also hold promise for the treatment of collagen diseases, including systemic lupus erythematosus, systemic sclerosis, and vasculitis. However, drawbacks related to their use persist, including high drug costs and the risk of adverse events, such as infectious diseases. Therefore, the criteria for selecting patients who are most likely to benefit from these drugs should be developed.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	0
title_short	Molecular-Targeted Drugs in Rheumatology
url	https://doi.org/10.24488/twmuj.2023013 https://doaj.org/article/5084a4e248ad4c1baba7559183723690 https://www.jstage.jst.go.jp/article/twmuj/7/0/7_2023013/_pdf/-char/en https://doaj.org/toc/2432-6186
remote_bool	true
ppnlink	1751181464
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.24488/twmuj.2023013
up_date	2024-07-03T15:40:50.280Z
_version_	1803573002536747008
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ098147579</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413205201.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.24488/twmuj.2023013</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ098147579</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ5084a4e248ad4c1baba7559183723690</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Eiichi Tanaka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Molecular-Targeted Drugs in Rheumatology</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cell-surface antigens, cytokines, receptors, and signal transduction molecules that are central in the pathogenesis of rheumatic diseases have been elucidated, and therapeutic targets have been identified. Molecular-targeted drugs are now available for the treatment of rheumatoid arthritis and other diseases, including psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. These targeted drugs have shown the potential for achieving clinical remission in many rheumatic diseases. Tumor necrosis factor and interleukin-6 (IL-6) play major roles in rheumatoid arthritis, whereas IL-17 and IL-23 play crucial roles in spondyloarthritis. Biological disease-modifying anti-rheumatic drugs that specifically inhibit the actions of these cytokines and targeted synthetic disease-modifying anti-rheumatic drugs, such as Janus kinase inhibitors, have been approved, increasing the available treatment options. Molecular-targeted drugs also hold promise for the treatment of collagen diseases, including systemic lupus erythematosus, systemic sclerosis, and vasculitis. However, drawbacks related to their use persist, including high drug costs and the risk of adverse events, such as infectious diseases. Therefore, the criteria for selecting patients who are most likely to benefit from these drugs should be developed.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">biological disease-modifying anti-rheumatic drugs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">janus kinase inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">molecular-targeted drugs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">rheumatoid arthritis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">rheumatic diseases</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Tokyo Women's Medical University Journal</subfield><subfield code="d">Society of Tokyo Women's Medical University, 2021</subfield><subfield code="g">7(2023), 0, Seite 21-33</subfield><subfield code="w">(DE-627)1751181464</subfield><subfield code="x">24326186</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:0</subfield><subfield code="g">pages:21-33</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.24488/twmuj.2023013</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/5084a4e248ad4c1baba7559183723690</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.jstage.jst.go.jp/article/twmuj/7/0/7_2023013/_pdf/-char/en</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2432-6186</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2023</subfield><subfield code="e">0</subfield><subfield code="h">21-33</subfield></datafield></record></collection>
score	7.4020987

Nicht das Richtige dabei?

Schreiben Sie uns!

Molecular-Targeted Drugs in Rheumatology

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?